Last reviewed 2026-05-26 · How we verify

Mefrusid (MEFRUSIDE)

Phase 2 active Small molecule ✓ Verified May 2026

Mefrusid (generic name: MEFRUSIDE) is a mefruside drug. It is currently in Phase 2 development.

Mefruside works by inhibiting the sodium-potassium ATPase pump in the kidneys.

Mefruside is a small molecule. It is also known by the synonyms BAY 1500, BAY-1500, BAYCARON, MEFRUSIDA, and MEFRUSIDE.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MEFRUSIDE
Drug class	mefruside
Modality	Small molecule
Therapeutic area	Nephrology
Phase	Phase 2

Mechanism of action

Think of the sodium-potassium ATPase pump like a gatekeeper that helps regulate the balance of sodium and potassium in the body. When this pump is working properly, it helps remove excess sodium from the body and maintain healthy blood pressure. Mefruside blocks this pump, which can help reduce blood pressure in people with hypertension.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Mefrusid CI brief — competitive landscape report
Mefrusid updates RSS · CI watch RSS

Frequently asked questions about Mefrusid

What is Mefrusid?

Mefrusid (MEFRUSIDE) is a mefruside drug.

How does Mefrusid work?

Mefruside works by inhibiting the sodium-potassium ATPase pump in the kidneys.

What is the generic name of Mefrusid?

MEFRUSIDE is the generic (nonproprietary) name of Mefrusid.

What drug class is Mefrusid in?

Mefrusid belongs to the mefruside class. See all mefruside drugs at /class/mefruside.

What development phase is Mefrusid in?

Mefrusid is in Phase 2.

Drug class: All mefruside drugs
Therapeutic area: All drugs in Nephrology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing